Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Moderna says COVID-19 vaccine pricing to ensure broad access

Published 07/29/2020, 09:31 AM
Updated 07/29/2020, 09:50 AM
© Reuters. FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts
PFE
-
MRNA
-

(Reuters) - Moderna (NASDAQ:MRNA) Inc plans to price its experimental coronavirus vaccine in a way that ensures broad access, it said on Wednesday, adding that it did not intend to conduct late-stage trials of the vaccine outside the United States.

Moderna began the U.S. government-backed trial on Monday, among a handful of companies that have started final testing of their experimental vaccines on tens of thousands of healthy volunteers.

Chief Executive Officer Stéphane Bancel declined to comment on the specific price of the vaccine on a conference call with analysts.

"We are highly aware of our obligation during the pandemic phase to be responsible in how we price the vaccine," Bancel said.

The Financial Times reported on Tuesday, citing unnamed sources, that the company was planning to price the vaccine at $50 to $60 per course, at least $11 more than another vaccine from Pfizer Inc (NYSE:PFE) and BioNTech.

© Reuters. FILE PHOTO: Moderna Therapeutics seen during COVID-19 in Massachusetts

Moderna executives also said the enrollment for the late-stage trial was on track and the company had seen tremendous interest from clinical sites.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.